DermBiont is a clinical stage biotech company with multiple active INDs enabling multiple Phase 2 clinical trials. Assuming positive results in the current trials the two lead products will advance to Phase 3 trials in the coming year or two. The two lead products are for the treatment of seborrheic keratosis and for the treatment of hyperpigmentation disorders of the skin. The company aims to be the leading targeted topical therapeutics development company. This is facilitated by leveraging decades of combined team experience to select and develop first-in-class assets with the highest probability of success in the clinic, defining clear regulatory strategies, and conducting efficient clinical trials. DermBiont works continually to create an environment that supports and empowers our employees to do their best work.